Literature DB >> 23934595

Fusariosis, a complex infection caused by a high diversity of fungal species refractory to treatment.

J Guarro1.   

Abstract

In recent years the number of opportunistic invasive fusariosis has increased significantly, the main factors involved in these infections being reviewed here. In spite of the extensive literature published the advances in the management of disseminated fusariosis have been very poor and it remains a severe infection, refractory to treatment and with a high mortality rate. There are no ideal therapies and the presence of neutropenia has a critical part to play in the outcome of the infection. At least 70 species have been involved in fusariosis. Fusarium solani species complex is responsible for nearly 60% of the cases and F. oxysporum species complex for approximately 20% of them. Most of the infections are caused by four species, i.e. F. petroliphilum, F. keratoplasticum and other two unnamed phylogenetic species. The efficacy of amphotericin B and voriconazole, the most used antifungal drugs, for treating invasive fusariosis are controversial but in general the percentage of patients cured in the different clinical trials is low. Infections by Fusarium verticillioides seem to have the best prognosis. The recent release of complete genome sequences of the most clinically relevant species and the emergence of fungal genomics offer excellent opportunities for examining the multifactorial processes of Fusarium pathogenicity. Using knockout mutants of genes encoding sequence-specific proteins, several virulence factors have been characterized.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23934595     DOI: 10.1007/s10096-013-1924-7

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  72 in total

1.  Resolution of fungemia due to Fusarium species in a patient with acute leukemia treated with caspofungin.

Authors:  John Apostolidis; Maria Bouzani; Evangelia Platsouka; Helen Belasiotou; Maria Stamouli; Nikolaos Harhalakis; Eleni I Boutati; Olga Paniara; Emmanuel Nikiforakis
Journal:  Clin Infect Dis       Date:  2003-05-15       Impact factor: 9.079

2.  Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex.

Authors:  John R Perfect
Journal:  Clin Infect Dis       Date:  2005-05-01       Impact factor: 9.079

3.  Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models.

Authors:  F C Odds; F Van Gerven; A Espinel-Ingroff; M S Bartlett; M A Ghannoum; M V Lancaster; M A Pfaller; J H Rex; M G Rinaldi; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

Review 4.  Combination antifungal therapy for disseminated fusariosis in immunocompromised patients : a case report and literature review.

Authors:  Jyh-You Liu; Wei-Ting Chen; Bor-Sheng Ko; Ming Yao; Po-Ren Hsueh; Cheng-Hsiang Hsiao; Yu-Min Kuo; Yee-Chun Chen
Journal:  Med Mycol       Date:  2011-03-30       Impact factor: 4.076

5.  Mixed infection caused by two species of Fusarium in a human immunodeficiency virus-positive patient.

Authors:  J Guarro; M Nucci; T Akiti; J Gené
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

6.  Use of mass spectrometry to identify clinical Fusarium isolates.

Authors:  C Marinach-Patrice; A Lethuillier; A Marly; J-Y Brossas; J Gené; F Symoens; A Datry; J Guarro; D Mazier; C Hennequin
Journal:  Clin Microbiol Infect       Date:  2009-05-18       Impact factor: 8.067

7.  Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection.

Authors:  Marcio Nucci; Elias J Anaissie; Flavio Queiroz-Telles; Carlos A Martins; Plínio Trabasso; Cristiana Solza; Claudia Mangini; Belinda P Simões; Arnaldo L Colombo; Jorge Vaz; Carlos E Levy; Silvia Costa; Vaneusa A Moreira; José Salvador Oliveira; Nestor Paraguay; Gisele Duboc; Julio C Voltarelli; Angelo Maiolino; Ricardo Pasquini; Cármino A Souza
Journal:  Cancer       Date:  2003-07-15       Impact factor: 6.860

8.  Synergysm of voriconazole or itraconazole with other antifungal agents against species of Fusarium.

Authors:  Tatiana B Spader; Tarcieli P Venturini; Luana Rossato; Laura B Denardi; Patricia B Cavalheiro; Sonia A Botton; Janio M Santurio; Sydney Hartz Alves
Journal:  Rev Iberoam Micol       Date:  2013-02-09       Impact factor: 1.044

9.  Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases.

Authors:  T J Walsh; J W Hiemenz; N L Seibel; J R Perfect; G Horwith; L Lee; J L Silber; M J DiNubile; A Reboli; E Bow; J Lister; E J Anaissie
Journal:  Clin Infect Dis       Date:  1998-06       Impact factor: 9.079

10.  Molecular phylogenetic diversity of dermatologic and other human pathogenic fusarial isolates from hospitals in northern and central Italy.

Authors:  Quirico Migheli; Virgilio Balmas; Henry Harak; Silvana Sanna; Barbara Scherm; Takayuki Aoki; Kerry O'Donnell
Journal:  J Clin Microbiol       Date:  2010-01-27       Impact factor: 5.948

View more
  58 in total

1.  In Vitro Susceptibility of Fusarium to Isavuconazole.

Authors:  A Broutin; J Bigot; Y Senghor; A Moreno-Sabater; J Guitard; C Hennequin
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

2.  Keratitis due to Fusarium langsethiae: clinical profile, molecular identification, and susceptibility to antifungals.

Authors:  Vasanthakumar Vasantha Ruban; Pitchairaj Geraldine; Jayaraman Kaliamurthy; Christadoss Arul Nelson Jesudasan; Philip Aloysius Thomas
Journal:  Mycopathologia       Date:  2015-02-03       Impact factor: 2.574

3.  Genus-Specific Primers for Study of Fusarium Communities in Field Samples.

Authors:  Ida Karlsson; Véronique Edel-Hermann; Nadine Gautheron; Mikael Brandström Durling; Anna-Karin Kolseth; Christian Steinberg; Paula Persson; Hanna Friberg
Journal:  Appl Environ Microbiol       Date:  2015-10-30       Impact factor: 4.792

4.  Demonstration of Adventitious Sporulation in Fusarium Petroliphilum Onychomycosis.

Authors:  Ziauddin Khan; Suhail Ahmad; Wadha Alfouzan; Leena Joseph; Soumya Varghese
Journal:  Mycopathologia       Date:  2019-02-08       Impact factor: 2.574

5.  Generic concepts in Nectriaceae.

Authors:  L Lombard; N A van der Merwe; J Z Groenewald; P W Crous
Journal:  Stud Mycol       Date:  2015-01-29       Impact factor: 16.097

6.  Flow Cytometry Is a Powerful Tool for Assessment of the Viability of Fungal Conidia in Metalworking Fluids.

Authors:  D Vanhauteghem; K Demeyere; N Callaert; A Boelaert; G Haesaert; K Audenaert; E Meyer
Journal:  Appl Environ Microbiol       Date:  2017-08-01       Impact factor: 4.792

Review 7.  Granulocyte transfusions: A concise review for practitioners.

Authors:  Juan Gea-Banacloche
Journal:  Cytotherapy       Date:  2017-09-12       Impact factor: 5.414

8.  Clinical Spectrum, Diagnosis and Outcome of Rare Fungal Infections in Patients with Hematological Malignancies: Experience of 15-Year Period from a Single Tertiary Medical Center.

Authors:  Emilia Hardak; Eyal Fuchs; Yuval Geffen; Tsila Zuckerman; Ilana Oren
Journal:  Mycopathologia       Date:  2020-02-25       Impact factor: 2.574

9.  Potent Activities of Luliconazole, Lanoconazole, and Eight Comparators against Molecularly Characterized Fusarium Species.

Authors:  Mahdi Abastabar; Abdullah M S Al-Hatmi; Mohammad Vafaei Moghaddam; G Sybren de Hoog; Iman Haghani; Seyed Reza Aghili; Tahereh Shokohi; Mohammad Taghi Hedayati; Roshanak Daie Ghazvini; Reza Kachuei; Ali Rezaei-Matehkolaei; Koichi Makimura; Jacques F Meis; Hamid Badali
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

10.  A Clonal Lineage of Fusarium oxysporum Circulates in the Tap Water of Different French Hospitals.

Authors:  Véronique Edel-Hermann; Marc Sautour; Nadine Gautheron; Julie Laurent; Serge Aho; Alain Bonnin; Nathalie Sixt; Philippe Hartemann; Frédéric Dalle; Christian Steinberg
Journal:  Appl Environ Microbiol       Date:  2016-10-14       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.